News coverage about GW Pharmaceuticals PLC- (NASDAQ:GWPH) has been trending somewhat positive this week, according to AlphaOne Sentiment. AlphaOne, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GW Pharmaceuticals PLC- earned a daily sentiment score of 0.15 on AlphaOne’s scale. AlphaOne also gave news articles about the biopharmaceutical company an impact score of 25 out of 100, indicating that recent media coverage is very unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted AlphaOne Sentiment Analysis’s analysis:
- GW Pharmaceuticals PLC- (GWPH) Given “Buy” Rating at Maxim Group (americanbankingnews.com)
- 2 New Ways To Invest In Marijuana Stocks: Cannabis ETFs (finance.yahoo.com)
- Op-Ed: The US is falling behind other countries—like Canada—on marijuana (finance.yahoo.com)
- GW Pharma And Its U.S. Subsidiary Highlight New Epidiolex (Cannabidiol) Data Released By The American Academy of Neurology (biospace.com)
- GW Pharma (GWPH) Highlights New Epidiolex Data Released by AAN (streetinsider.com)
GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded down 0.47% on Friday, hitting $115.28. 97,966 shares of the company traded hands. The firm’s 50 day moving average price is $121.30 and its 200 day moving average price is $121.10. The firm’s market capitalization is $2.91 billion. GW Pharmaceuticals PLC- has a 1-year low of $74.05 and a 1-year high of $137.88.
GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings results on Tuesday, February 7th. The biopharmaceutical company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($1.35) by $0.58. GW Pharmaceuticals PLC- had a negative return on equity of 20.07% and a negative net margin of 702.90%. The business earned $2.54 million during the quarter, compared to analyst estimates of $1.85 million. During the same period last year, the business posted ($0.06) earnings per share. The company’s quarterly revenue was down 32.4% on a year-over-year basis. Equities research analysts predict that GW Pharmaceuticals PLC- will post ($5.07) EPS for the current fiscal year.
Several analysts recently issued reports on the stock. Maxim Group began coverage on shares of GW Pharmaceuticals PLC- in a research report on Thursday. They issued a “buy” rating and a $135.00 price target for the company. TheStreet raised shares of GW Pharmaceuticals PLC- from a “d+” rating to a “c-” rating in a report on Tuesday, March 14th. Goldman Sachs Group Inc reissued a “buy” rating and issued a $185.00 price target on shares of GW Pharmaceuticals PLC- in a report on Wednesday, February 22nd. Cowen and Company set a $135.00 price target on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a report on Monday, February 6th. Finally, Piper Jaffray Companies set a $147.00 price target on shares of GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a report on Tuesday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $144.50.
TRADEMARK VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/04/21/somewhat-positive-press-coverage-very-unlikely-to-effect-gw-pharmaceuticals-plc-gwph-stock-price-updated.html.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.